Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT. (June 2017)

• Record Type: Journal Article
• Authors: Kato, Masaki; Takekita, Yoshiteru; Koshikawa, Yosuke; Sakai, Shiho; Bandou, Hiroki; Nishida, Keiichiro; Sunada, Naotaka; Onohara, Ai; Hatashita, Yoshiyuki; Serretti, Alessandro; Kinoshita, Toshihiko
• Is Part Of: Journal of psychiatric research. Volume 89(2017)
• Page Start: 97
• Page End: 104
• Publication Date: 2017-06
• Subjects: Randomized controlled trial -- Antidepressant combination -- Non response -- Mirtazapine -- SSRI -- Major depressive disorder; Psychiatry -- Periodicals; Mental Disorders -- Periodicals; Maladies mentales -- Périodiques; Psychiatry; Electronic journals; Periodicals; 616.89005
• DOI: 10.1016/j.jpsychires.2017.02.003
• Languages: English
• ISSNs: 0022-3956

Abstract

Abstract: We aimed to compare the efficacy and tolerability of mirtazapine versus SSRIs and to assess whether "non-response at week 4" may be a clinical indicator for combining mirtazapine and SSRIs for subsequent treatment. One-hundred fifty-four outpatients with MDD were randomized to receive mirtazapine or SSRIs in step I (4 weeks). Non-responders in step I were randomly assigned to either mirtazapine or SSRIs monotherapy or their combination in step IIa while responders in step I continued the same monotherapy in step IIb for 4 weeks. In step I, mirtazapine showed significantly faster improvement as shown by higher remission rate at week 2 with NNT = 8 compared to SSRIs. Somnolence rate was higher in mirtazapine and nausea rate was higher in SSRIs. In step IIa, combination therapy showed a more favorable time course than SSRIs monotherapy. For subjects taking SSRIs in step I, combination therapy showed significant better improvement in the Hamilton Depression Rating (HAM-D) score both at week 6 (p = 0.006) and 8 (p = 0.013) than SSRIs monotherapy. About 80% of responders at week 4 could reach remission at week 8 and 64% of non-responders could not reach remission at week 8 for patients who continued monotherapy. When mirtazapine was added on for SSRIs non-responders at week 4, the remission rate increased by 5% and HAM-D score improved by 4 points. While for mirtazapine non-responders, SSRIs add-on was not equally effective. Mirtazapine may provide a faster improvement and "non-response at week 4" may be indicator to mirtazapine add-on for patients receiving SSRIs.